Jeremie Calais

Jeremie Calais is a distinguished physician and researcher with a focus on molecular and medical pharmacology. He holds the position of Associate Clinical Professor in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), a role he has embraced since 2013. Dr. Calais has made significant contributions as both a principal investigator and co-investigator in numerous clinical trials, particularly those centered on the evaluation of innovative diagnostic and therapeutic agents for prostate cancer. His research is primarily concentrated on the development of cutting-edge radiopharmaceuticals aimed at enhancing imaging and therapeutic strategies for prostate cancer. Additionally, Dr. Calais is dedicated to the validation of novel imaging biomarkers, which play a crucial role in the early detection and monitoring of treatment responses in cancer patients. His work in this area is pivotal in advancing the field of cancer diagnostics and treatment. Dr. Calais is an active member of several esteemed professional organizations, reflecting his commitment to the advancement of his field. These include the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American Association for Cancer Research (AACR), and the American Society of Clinical Oncology (ASCO). Through his involvement in these organizations, he contributes to the ongoing dialogue and development of best practices in nuclear medicine and oncology. His dedication to research and clinical excellence has positioned him as a leading figure in his field, where he continues to push the boundaries of what is possible in cancer treatment and diagnostics. Dr. Calais's work not only impacts the scientific community but also holds promise for improving patient outcomes in the realm of oncology.